PhaseBio Pharmaceuticals Inc (PHAS)

NASDAQ
1.950
-0.040(-2.01%)
After Hours
1.935
-0.015(-0.769%)
- Real-time Data
  • Volume:
    832,382
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.880 - 2.011

PHAS Overview

Prev. Close
1.99
Day's Range
1.88-2.011
Revenue
10.68M
Open
1.99
52 wk Range
1.85-5.74
EPS
-3.17
Volume
832,382
Market Cap
93.78M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
659,205
P/E Ratio
-
Beta
-
1-Year Change
-54.01%
Shares Outstanding
48,089,983
Next Earnings Date
Mar 29, 2022
What is your sentiment on PhaseBio Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

PhaseBio Pharmaceuticals Inc Company Profile

Employees
60

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellBuyStrong BuyStrong SellStrong Sell
SummaryStrong SellNeutralStrong SellStrong SellStrong Sell
  • Hello? 👀
    0
    • 8.5 aim 17
      2
      • 7.35 aim for 15
        1
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.